Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 232 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer... March 19, 2020 How to Talk With Your Children About Your Metastatic Cancer Prognosis September 2, 2021 Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab... June 10, 2024 Can I Have a Non-Violent Relationship with Cancer (Part 2) November 16, 2021 Load more HOT NEWS Can Eating Soy Cause Breast Cancer? Addressing Cancer Pain with Complementary Methods (Part 2) FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer Using a Mind-Body Connection to Help You Cope During Cancer: An...
